Loading...

Home
ETF
CINGW

CINGW

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

CINGW News

Cingulate's Top ADHD Candidate CTx-1301 Chosen for Podium Presentation at AACAP Annual Meeting

Oct 23 2025Newsfilter

Cingulate Forms Exclusive Manufacturing Alliance with Bend Bio Sciences for Upcoming ADHD Treatment Commercialization

Sep 17 2025Newsfilter

Cingulate Inc. Announces Financial Results for Q2 2025 and Shares Recent Developments

Aug 19 2025Newsfilter

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Aug 06 2025Newsfilter

Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301

Jul 29 2025Newsfilter

FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301

May 14 2025Newsfilter

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

May 08 2025Newsfilter

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Apr 09 2025Newsfilter

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Mar 26 2025Newsfilter

Final Study Completed for Cingulate's Lead Asset CTx-1301

Jan 07 2025Newsfilter

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Dec 23 2024Newsfilter

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Nov 07 2024Newsfilter

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Oct 08 2024Newsfilter

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Sep 12 2024Newsfilter

Cingulate to Participate in Benzinga All Live Access Event

Aug 27 2024Newsfilter

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 15 2024Newsfilter